Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

AML1/ETO, AML1, and HEB binding patterns on chromosme 19


ABSTRACT: Approximately 20% of Acute Myelogenous Leukemia (AML) cases carry the t(8;21) translocation, which involves the AML1 and ETO genes, and express the resulting AML1/ETO fusion protein that functions as a transcriptional repressor by recruiting NCoR/SMRT/HDAC complexes to DNA. We used ChIP-chip to identify the determinants of AML1/ETO binding on a contiguous DNA region (chromosome 19). AML1/ETO binding regions are characterized by a specific sequence signature that includes the presence of the consensus binding sites for the AML1 and HEB transcription factors. We therefore assessed the binding patterns of AML1 and HEB on chromosome 19. A specific chromatin modification (tri-methylation of lysine 4 on histone 3 = 3MetK4) was also studied in U937 cells expressing AML1/ETO in order to correlate the identified binding profiles with active transcription sites. Keywords: ChIP-chip A U937 cell line that conditionally expresses HA-tagged AML1/ETO under the control of the mouse metallothionine promoter (U937-A1E) (Alcalay et al., J.Clin.Invest, 2003,112, 1751-1761) was used. Cell lines were treated for 8h with 100uM ZnSO4 to induce transgene expression in U937-A1E. We performed ChIP using anti-HA, anti-ETO, anti-AML1/RUNX1, anti-HEBor anti-3MetK4 antibodies. ChIP products were then PCR amplified, labeled with Cy3/Cy5 fluorescent dyes and hybridized to the NimbleGen custom made NGS_HG17_Chr.19Array. U937-Mt cells, which carry the empty vector, served as control (C) for non-specific antibody binding. Each sample identifier indicates Antibody_Cell line (example: HA_A1E = ChIP using anti HA antibody in U937-A1E cells; HA_C = ChIP using anti HA antibody in U937-Mt control cells)

ORGANISM(S): Homo sapiens

SUBMITTER: Myriam Alcalay 

PROVIDER: E-GEOD-10578 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.

Gardini Alessandro A   Cesaroni Matteo M   Luzi Lucilla L   Okumura Akiko J AJ   Biggs Joseph R JR   Minardi Simone P SP   Venturini Elisa E   Zhang Dong-Er DE   Pelicci Pier Giuseppe PG   Alcalay Myriam M  

PLoS genetics 20081128 11


A reciprocal translocation involving chromosomes 8 and 21 generates the AML1/ETO oncogenic transcription factor that initiates acute myeloid leukemia by recruiting co-repressor complexes to DNA. AML1/ETO interferes with the function of its wild-type counterpart, AML1, by directly targeting AML1 binding sites. However, transcriptional regulation determined by AML1/ETO probably relies on a more complex network, since the fusion protein has been shown to interact with a number of other transcriptio  ...[more]

Similar Datasets

2008-12-21 | E-GEOD-10531 | biostudies-arrayexpress
2010-06-24 | E-GEOD-10579 | biostudies-arrayexpress
2008-11-28 | GSE10578 | GEO
2010-06-24 | E-GEOD-10537 | biostudies-arrayexpress
2009-01-13 | E-GEOD-10520 | biostudies-arrayexpress
2015-11-04 | E-GEOD-65427 | biostudies-arrayexpress
2013-06-20 | E-GEOD-43834 | biostudies-arrayexpress
2008-12-22 | GSE10531 | GEO
2009-05-01 | GSE15647 | GEO
2008-11-28 | GSE10520 | GEO